{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:56:12Z","timestamp":1787068572873,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:p>\n                    Accurate diagnosis of liver cirrhosis (LC) and significant fibrosis in patients with chronic liver disease (CLD) is important. The Mac-2 binding protein glycosylation isomer (M2BPGi) has emerged as a novel serum biomarker for liver fibrosis; however, insufficient clinical data of M2BPGi are available in patients with CLD. Therefore, we performed a retrospective cohort study to investigate the clinical usefulness of serum M2BPGi for assessing LC and significant fibrosis in CLD patients. We retrospectively reviewed the CLD patients with measured serum M2BPGi at Kosin University Gospel Hospital between January 2016 and December 2019. Multivariate logistic regression analyses were conducted to identify the independent factors associated with LC. The diagnostic power of serum M2BPGi for LC and significant fibrosis (\u2265F2) was evaluated and compared to that of other serum biomarkers using receiver operating characteristic curve and area under the curve (AUC). A total of 454 patients enrolled in this study. M2BPGi (adjusted odds ratio [aOR], 1.77; 95% confidence interval [CI], 1.52\u20132.07) and fibrosis index based on four factors (aOR, 1.23; 95% CI, 1.11\u20131.37) were identified as significant independent factors for LC. The AUC of M2BPGi for LC (0.866) and significant fibrosis (0.816) were comparable to those of fibrosis index based on four factors (0.860, 0.773), aspartate aminotransferase-to-platelet ratio index (0.806, 0.752), and gamma-glutamyl transpeptidase-to-platelet ratio (0.759, 0.710). The optimal cut-off values for M2BPGi for LC and significant fibrosis were 1.37 and 0.89, respectively. Serum M2BPGi levels were significantly correlated with liver stiffness measurements (\n                    <jats:italic toggle=\"yes\">\u03c1<\/jats:italic>\n                    \u2005=\u20050.778). Serum M2BPGi is a reliable noninvasive method for the assessment of LC and significant fibrosis in patients with CLD.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000030489","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T10:50:06Z","timestamp":1665399006000},"page":"e30489","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Clinical usefulness of Mac-2 binding protein glycosylation isomer for diagnosing liver cirrhosis and significant fibrosis in patients with chronic liver disease: A retrospective single-center study"],"prefix":"10.1097","volume":"101","author":[{"given":"Hyun Joon","family":"Park","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea"},{"name":"Chang Kee-Ryo Memorial Liver Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8854-5205","authenticated-orcid":false,"given":"Kwang Il","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea"},{"name":"Chang Kee-Ryo Memorial Liver Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Uk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea"},{"name":"Chang Kee-Ryo Memorial Liver Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Hoon","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea"},{"name":"Chang Kee-Ryo Memorial Liver Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Cheol","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea"},{"name":"Chang Kee-Ryo Memorial Liver Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Taek","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea"},{"name":"Chang Kee-Ryo Memorial Liver Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea"},{"name":"Chang Kee-Ryo Memorial Liver Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunyong","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myunghee","family":"Yoon","sequence":"additional","affiliation":[{"name":"Division of Hepatobiliary and Pancreas Surgery, Department of Surgery Biomedical Research Institute, Pusan National University, College of Medicine, Busan, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199306243282508","article-title":"Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies.","volume":"328","author":"Friedman","year":"1993","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0168-8278(02)00413-0","article-title":"A comparison of fibrosis progression in chronic liver diseases.","volume":"38","author":"Poynard","year":"2003","journal-title":"J Hepatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks.","volume":"68","author":"D\u2019Amico","year":"2018","journal-title":"J Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"issue":"Suppl 6","key":"R5-20250504","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.3350\/kjhep.2009.15.S6.S40","article-title":"Current status of liver diseases in Korea: liver cirrhosis.","volume":"15","author":"Jang","year":"2009","journal-title":"Korean J Hepatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40265-015-0401-2","article-title":"Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.","volume":"75","author":"Majumdar","year":"2015","journal-title":"Drugs"},{"issue":"Suppl 1","key":"R7-20250504","first-page":"S1","article-title":"Introduction to chronic hepatitis B infection.","volume":"101","author":"Wright","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","article-title":"Liver biopsy.","volume":"344","author":"Bravo","year":"2001","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/jhep.2000.16602","article-title":"Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the French Association for the Study of the Liver (AFEF).","volume":"32","author":"Cadranel","year":"2000","journal-title":"Hepatology"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-8278(03)00191-0","article-title":"Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.","volume":"39","author":"Colloredo","year":"2003","journal-title":"J Hepatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.20535","article-title":"Sources of variability in histological scoring of chronic viral hepatitis.","volume":"41","author":"Rousselet","year":"2005","journal-title":"Hepatology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","article-title":"Non-invasive diagnosis of liver fibrosis and cirrhosis.","volume":"21","author":"Lurie","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest.","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/jvh.12842","article-title":"Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.","volume":"25","author":"Liu","year":"2018","journal-title":"J Viral Hepat"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study.","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.21420","article-title":"Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases.","volume":"44","author":"Ganne-Carri\u00e9","year":"2006","journal-title":"Hepatology"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"R20-20250504","first-page":"e40737","article-title":"Performance and utility of transient elastography and non-invasive markers of liver fibrosis in patients with autoimmune hepatitis: a single centre experience.","volume":"16","author":"O","year":"2016","journal-title":"Hepat Mon"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2893.2006.00811.x","article-title":"Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.","volume":"14","author":"Coco","year":"2007","journal-title":"J Viral Hepat"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/hep.22577","article-title":"Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis.","volume":"48","author":"Millonig","year":"2008","journal-title":"Hepatology"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2009.11.018","article-title":"Liver stiffness is directly influenced by central venous pressure.","volume":"52","author":"Millonig","year":"2010","journal-title":"J Hepatol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/srep01065","article-title":"A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.","volume":"3","author":"Kuno","year":"2013","journal-title":"Sci Rep"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/prca.201300010","article-title":"Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling.","volume":"7","author":"Kuno","year":"2013","journal-title":"Proteomics Clin Appl"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12876-017-0618-5","article-title":"Accuracy of M2BPGi, compared with Fibro Scan\u00ae, in analysis of liver fibrosis in patients with hepatitis C.","volume":"17","author":"Xu","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1111\/hepr.12724","article-title":"Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C.","volume":"47","author":"Nishikawa","year":"2017","journal-title":"Hepatol Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41424-018-0020-9","article-title":"Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.","volume":"9","author":"Mak","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/liv.13188","article-title":"Serum WFA(+) -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection.","volume":"37","author":"Zou","year":"2017","journal-title":"Liver Int"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1365-2036.2008.03831.x","article-title":"Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.","volume":"28","author":"Nguyen-Khac","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","article-title":"Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease.","volume":"50","author":"Abe","year":"2015","journal-title":"J Gastroenterol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/hepr.12596","article-title":"Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis.","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ajg.2015.118","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis.","volume":"110","author":"Umemura","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00535-017-1425-z","article-title":"Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.","volume":"53","author":"Shirabe","year":"2018","journal-title":"J Gastroenterol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.510230513","article-title":"Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study.","volume":"23","author":"Becker","year":"1996","journal-title":"Hepatology"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/14789450.2015.1084874","article-title":"Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis\/cirrhosis diagnostics.","volume":"12","author":"Narimatsu","year":"2015","journal-title":"Expert Rev Proteomics"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography.","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/jgh.13708","article-title":"Hepatic stellate cells secreting WFA(+) -M2BP: Its role in biological interactions with Kupffer cells.","volume":"32","author":"Bekki","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"R40-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jgh.12017","article-title":"Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?","volume":"28","author":"Yi","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"e0174982","DOI":"10.1371\/journal.pone.0174982","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease.","volume":"12","author":"Lai","year":"2017","journal-title":"PLoS One"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3343\/alm.2018.38.4.331","article-title":"Usefulness of enhanced liver fibrosis, glycosylation isomer of Mac-2 binding protein, galectin-3, and soluble suppression of tumorigenicity 2 for assessing liver fibrosis in chronic liver diseases.","volume":"38","author":"Moon","year":"2018","journal-title":"Ann Lab Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:39:28Z","timestamp":1746319168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":42,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030489","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}